Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection

Co-chairs: GW McCaughan, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia M Omata, Tokyo University Hospital, Tokyo, Japan Faculty Members: D Amarapurkar, Bombay Hospital, Mumbai, India S Bowden, Victorian Infectious Diseases Reference Laboratories, Melbourne, Australia WC Chow, Singapore General Hospital, Singapore A Chutaputti, Pramongkutklao Hospital, Bangkok, Thailand G Dore, National Center in HIV Epidemiology and Clinical Research, Sydney, Australia E Gane, NZ Liver Transplant Unit, Auckland, New Zealand R Guan, Mount Elizabeth Medical Center, Singapore SS Hamid, The Aga Khan University, Karachi, Pakistan W Hardikar, Royal Children’s Hospital, Melbourne, Australia CK Hui, Queen Mary Hospital, University of Hong Kong, Hong Kong, China W Jafri, The Aga Khan University, Karachi, Pakistan J-D Jia, Beijing Friendship Hospital, Capital Medical University, Beijing, China M-Y Lai, National Taiwan University Hospital, Taiwan L Wei, Peking University Peoples Hospital, Beijing, China N Leung, The Chinese University of Hong Kong, Hong Kong, China T Piratvisuth, Prince of Songkla University, Hat Yai, Thailand S Sarin, GB Pant Hospital, Delhi, India J Sollano, University Santo Tomas Hospital, Manilla, Philippines R Tateishi, University of Tokyo Hospital, Tokyo Japan

[1]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[2]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[3]  R. Fisher,et al.  Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  M. A. al Karawi,et al.  Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. , 1997, Hepato-gastroenterology.

[5]  G. Farrell Consensus among consensus conferences on management of hepatitis C: What we knew then and are still sure about, what we are newly sure about, and what we still need to know , 2000, Journal of gastroenterology and hepatology.

[6]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[7]  Willis C. Maddrey,et al.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. , 1999, Journal of hepatology.

[8]  Y. Liaw Role of hepatitis C virus in dual and triple hepatitis virus infection , 1995, Hepatology.

[9]  E. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[10]  L. Rostaing,et al.  Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. , 1995, Transplantation.

[11]  S. Polywka,et al.  Accuracy of HCV‐RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection , 2006, Journal of medical virology.

[12]  J. Sánchez-Tapias,et al.  Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. , 2002, Transplantation.

[13]  H. Nomura,et al.  Short‐term interferon‐alfa therapy for acute hepatitis C: A randomized controlled trial , 2004, Hepatology.

[14]  M. Chevallier,et al.  [Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients]. , 2003, Gastroenterologie clinique et biologique.

[15]  B. Portmann,et al.  Long-term outcome of hepatitis C infection after liver transplantation. , 1996, The New England journal of medicine.

[16]  J. Mir,et al.  Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation , 2000, Hepatology.

[17]  D. Yeshurun,et al.  Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. , 2000, Clinical and experimental rheumatology.

[18]  B. Portmann,et al.  Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. , 1993, Journal of hepatology.

[19]  V. Yu,et al.  Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. , 1996, Surgery.

[20]  W. Kim,et al.  Burden of liver disease in the United States: Summary of a workshop , 2002, Hepatology.

[21]  M. Manns,et al.  High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection , 2004, Journal of medical virology.

[22]  M. Kedda,et al.  The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. , 1997, Gastroenterology.

[23]  K. Batts,et al.  Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  A. Chutaputti Adverse effects and other safety aspects of the hepatitis C antivirals , 2000, Journal of gastroenterology and hepatology.

[25]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[26]  S. Agarwal,et al.  Hepatitis C virus related cryoglobulinemic glomerulonephritis. , 2002, Journal of Association of Physicians of India.

[27]  K. Reddy,et al.  Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. , 1998, Transplantation.

[28]  L. Rostaing,et al.  Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  R. W. Mccollum The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.

[30]  J. Ware,et al.  Health‐related quality of life in chronic hepatitis C: Impact of disease and treatment response , 1999, Hepatology.

[31]  G. Cilla,et al.  Maternal-infant transmission of hepatitis C virus infection. , 1992, The Pediatric infectious disease journal.

[32]  M. Houghton,et al.  Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. , 1998, Gastroenterology.

[33]  A. Moya,et al.  Contribution of donor age to the recent decrease in patient survival among HCV‐infected liver transplant recipients , 2002, Hepatology.

[34]  William M. Lee,et al.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.

[35]  J. Hoofnagle,et al.  Hepatitis C and renal disease: an update. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  A. Levey,et al.  THE IMPACT OF PRETRANSPLANTATION HEPATITIS C INFECTION ON THE OUTCOME OF RENAL TRANSPLANTATION , 1995, Transplantation.

[37]  K. Reddy,et al.  Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. , 2004, Gastroenterology.

[38]  J. Crespo,et al.  Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. , 1994, The American journal of gastroenterology.

[39]  M. Buti,et al.  Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference , 2001, Hepatology.

[40]  Edward A Belongia,et al.  National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.

[41]  British Society of Gastroenterology , 1963 .

[42]  G. Everson,et al.  Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy , 2005, Hepatology.

[43]  A. Levey,et al.  Hepatitis C virus infection in dialysis and renal transplantation. , 1997, Kidney international.

[44]  Y. Jeng,et al.  Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients , 2003, Hepatology.

[45]  M. Narkewicz,et al.  Safety, Efficacy and Pharmacokinetics of Peginterferon &agr;2a (40 kd) in Children With Chronic Hepatitis C , 2006, Journal of pediatric gastroenterology and nutrition.

[46]  D. Payawal,et al.  Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? , 1997, Cancer.

[47]  J. Crowe,et al.  Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. , 1999, European journal of gastroenterology & hepatology.

[48]  O. Chazouilleres,et al.  Determinants of outcome of compensated hepatitis C virus‐related cirrhosis , 1998, Hepatology.

[49]  Z. Gaciong,et al.  Long-term results of treatment of chronic hepatitis B, C and D with interferon-α in renal allograft recipients , 1998 .

[50]  R. Beasley A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. , 2005, The Journal of infectious diseases.

[51]  D. Trichopoulos,et al.  Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. , 1991, JAMA.

[52]  R. Busuttil,et al.  Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. , 1997, The American journal of gastroenterology.

[53]  P. Ferenci Treatment of hepatic encephalopathy. , 2001, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[54]  X. Forns,et al.  Hepatitis C virus kinetics during and immediately after liver transplantation , 2002, Hepatology.

[55]  T. Maisonobe,et al.  Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. , 2005, AIDS.

[56]  Has Afef Achbt [Indications for liver transplantation. Text of recommendations - short version]. , 2005, Gastroenterologie clinique et biologique.

[57]  W. Chow Hepatitis C: Retreatment and treatment of patients with renal failure , 2000, Journal of gastroenterology and hepatology.

[58]  J. Pawlotsky,et al.  Use of virologic assays in the diagnosis and management of hepatitis C virus infection. , 2005, Clinics in liver disease.

[59]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.

[60]  J. Gisbert,et al.  Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. , 2003, Journal of hepatology.

[61]  P. Glue,et al.  The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.

[62]  P. Simmonds,et al.  Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease. , 1995, Blood.

[63]  Aljack Ma,et al.  Dual infection with hepatitis C and B viruses : Clinical and histological study in Saudi patients , 1997 .

[64]  M. Alter,et al.  Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[65]  M. Alter,et al.  Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. , 2005, The Journal of infectious diseases.

[66]  B. Bastani,et al.  Kidney disease in patients with chronic hepatitis c , 2001, Current gastroenterology reports.

[67]  R. Gish,et al.  A model to predict severe HCV‐related disease following liver transplantation , 2003, Hepatology.

[68]  F. Carrat,et al.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.

[69]  M. Buti,et al.  Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. , 2006, Journal of hepatology.

[70]  D. Valla,et al.  Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. , 1994, Gastroenterology.

[71]  P. Pontisso,et al.  A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. , 1997, Blood.

[72]  A. Muñoz,et al.  The declining risk of post-transfusion hepatitis C virus infection. , 1992, The New England journal of medicine.

[73]  P. Marcellin,et al.  Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. , 2004, Journal of hepatology.

[74]  R. Rodby,et al.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. , 1993, Journal of the American Society of Nephrology : JASN.

[75]  N. Mateva,et al.  Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study. , 2004, Minerva gastroenterologica e dietologica.

[76]  V. Thakur,et al.  Alpha‐interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses , 1999, Journal of gastroenterology and hepatology.

[77]  U. Steinbrecher,et al.  Analysis of causes of death in liver transplant recipients who survived more than 3 years , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[78]  N. Barshes,et al.  The natural history of hepatitis C virus in pediatric liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[79]  W. Jiménez,et al.  Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.

[80]  J. Gisbert,et al.  Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection , 2005, Alimentary pharmacology & therapeutics.

[81]  B. Nathwani,et al.  Hepatitis C Virus Infection in Patients with B-Cell Non-Hodgkin Lymphoma , 1997, Annals of Internal Medicine.

[82]  Y. Liaw,et al.  Impact of acute hepatitis B virus superinfection on chronic hepatitis c virus infection , 2000, American Journal of Gastroenterology.

[83]  Sarin Sk What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C? , 2000 .

[84]  F. Chisari,et al.  Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection , 2001, The Journal of experimental medicine.

[85]  Y. Maor,et al.  Non‐invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? , 2006, Haemophilia.

[86]  J. Devlin,et al.  Indications for referral and assessment in adultliver transplantation: a clinical guideline , 1999, Gut.

[87]  E. Tanaka,et al.  Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. , 1992, The American journal of tropical medicine and hygiene.

[88]  M. García-Carrasco,et al.  Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. , 2003, Rheumatology.

[89]  E. Nicastri,et al.  Contamination by hepatitis B and C viruses in the dialysis setting. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[90]  W. Irving,et al.  A comprehensive study of the association between hepatitis C virus and glomerulopathy. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[91]  Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNA , 1999, Vox sanguinis.

[92]  P. Francioli,et al.  Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[93]  M. Quintana,et al.  High-Dose and Long-Term Therapy of α Interferon in Hemophiliac Patients With Chronic C Virus Hepatitis , 1998 .

[94]  J. Piette,et al.  Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[95]  N. Terrault,et al.  A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus–infected patients awaiting liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[96]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[97]  T. Honda,et al.  Anti‐HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin , 2006, Journal of thrombosis and haemostasis : JTH.

[98]  M. Deschaseaux,et al.  Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? , 2005, Transfusion.

[99]  Z. Goodman,et al.  Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. , 2001, Journal of hepatology.

[100]  B. Bacon,et al.  Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[101]  High doses of α-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: Long term results of a prospective randomized trial , 2001 .

[102]  G. Borelli,et al.  Hepatitis C Virus Infection in Patients with Essential Mixed Cryoglobulinemia , 1992, Annals of Internal Medicine.

[103]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[104]  B. Zimmerman,et al.  Hepatitis C, cryoglobulinemia, and cirrhosis: A meta‐analysis , 2002, Hepatology.

[105]  N. Key,et al.  Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa‐2b and ribavirin , 2002, Hepatology.

[106]  M. Newell,et al.  Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[107]  J. Pawlotsky,et al.  SERIAL QUANTITATIVE DETERMINATION OF HEPATITIS C VIRUS RNA LEVELS AFTER LIVER TRANSPLANTATION A USEFUL TEST FOR DIAGNOSIS OF HEPATITIS C VIRUS REINFECTION , 1995, Transplantation.

[108]  H. Bismuth,et al.  Liver Resection Versus Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients , 1993, Annals of surgery.

[109]  J. Kaldor,et al.  Public health challenges in hepatitis C virus infection , 2000, Journal of gastroenterology and hepatology.

[110]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[111]  C. Chu,et al.  Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[112]  M. Russo,et al.  Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety , 2003, American Journal of Gastroenterology.

[113]  R. Purcell,et al.  A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. , 1991, The New England journal of medicine.

[114]  G. Alexander,et al.  European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. , 1999, Gastroenterology.

[115]  F. Fabrizi,et al.  Meta‐analysis: interferon for the treatment of chronic hepatitis C in dialysis patients , 2003, Alimentary pharmacology & therapeutics.

[116]  R. Fontana,et al.  Noninvasive monitoring of patients with chronic hepatitis C , 2002, Hepatology.

[117]  D. Dieterich,et al.  Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy , 2004, AIDS.

[118]  R. Carithers Liver transplantation , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[119]  J. Campistol,et al.  Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[120]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[121]  W. Hardikar,et al.  The silent infection: should we be testing for perinatal hepatitis C and, if so, how? , 2006, The Medical journal of Australia.

[122]  L. Rostaing,et al.  Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. , 1996, Nephron.

[123]  M. Schwartz,et al.  Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation , 1995, Hepatology.

[124]  E. Tanaka,et al.  Natural history of acute hepatitis C , 2000, Journal of gastroenterology and hepatology.

[125]  A. Mocroft,et al.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.

[126]  F. Fabrizi,et al.  Hepatitis C Virus Antibody Status and Survival After Renal Transplantation: Meta‐Analysis of Observational Studies , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[127]  G. McCaughan,et al.  Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA‐positive volunteer blood donors , 1992, The Medical journal of Australia.

[128]  C. Graham,et al.  Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics , 2004, Hepatology.

[129]  P. Chossegros,et al.  Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. , 1997, Transplantation proceedings.

[130]  N. Terrault,et al.  Treating hepatitis C infection in liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[131]  R. Wiesner,et al.  Predictors of patient and graft survival following liver transplantation for hepatitis C , 1998, Hepatology.

[132]  J. Devlin,et al.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. , 1999 .

[133]  C. Chu,et al.  Simultaneous acute infections with hepatitis non-A, non-B, and B viruses , 1982, Digestive Diseases and Sciences.

[134]  H. Bonkovsky,et al.  Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north america , 1998, Hepatology.

[135]  M. Manns,et al.  Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C , 2004, Hepatology.

[136]  M. Delgado-Rodríguez,et al.  Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users , 1999, European Journal of Epidemiology.

[137]  G. Mazzucco,et al.  Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. , 2003, Kidney international.

[138]  Y. Liaw Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection , 2008, Journal of Gastroenterology.

[139]  G. D'Amico,et al.  Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[140]  Christophe Combet,et al.  Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes , 2005, Hepatology.

[141]  B. Portmann,et al.  A longitudinal analysis of hepatitis C virus replication following liver transplantation. , 1996, Gastroenterology.

[142]  A. Marrone,et al.  Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. , 2004, Journal of hepatology.

[143]  Á. Figuera,et al.  Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients , 2000, Bone Marrow Transplantation.

[144]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[145]  J. R. Contreras,et al.  A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection , 2005 .

[146]  P. Bioulac-Sage,et al.  Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus–reinfected liver , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[147]  C. Chu,et al.  Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. , 2004, Gastroenterology.

[148]  G. Fattovich,et al.  Hepatitis C virus infection in chronic hepatitis B virus carriers. , 1991, The Journal of infectious diseases.

[149]  J. Brown Interferon therapy reduces the risk for hepatocellular carcinoma , 2000, Gut.

[150]  S. Akhtar,et al.  Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan , 2006, BMC infectious diseases.

[151]  K. Ishak,et al.  Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo‐controlled double‐blind trial , 1998, Hepatology.

[152]  V. Arroyo,et al.  Compensated cirrhosis: Natural history and prognostic factors , 1987, Hepatology.

[153]  Y. Oshiro,et al.  Prevalence of hepatitis C virus infection in cases of B‐cell lymphoma in Japan , 2006, Histopathology.

[154]  A. Heath,et al.  Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNA , 1999, Vox Sanguinis.

[155]  A. Inati,et al.  Efficacy and tolerability of peginterferon alpha‐2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection , 2005, British journal of haematology.

[156]  Shou-Dong Lee,et al.  Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: Application and limitations of the polymerase chain reaction , 1994, Hepatology.

[157]  M. Andreu,et al.  Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. , 1993, Gastroenterology.

[158]  M. Quintana,et al.  High-dose and long-term therapy of alpha interferon in hemophiliac patients with chronic C virus hepatitis. , 1998, Blood.

[159]  K. Matsuo,et al.  Effect of hepatitis C virus infection on the risk of non‐Hodgkin's lymphoma: A meta‐analysis of epidemiological studies , 2004, Cancer science.

[160]  NIH Consensus Statement on Management of Hepatitis C: 2002. , 2002, NIH consensus and state-of-the-science statements.

[161]  K. Ruxrungtham,et al.  Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 , 2003, AIDS.

[162]  C. Chan,et al.  Superinfection with hepatitis C virus in patients with symptomatic chronic hepatitis B. , 1991, Scandinavian journal of infectious diseases.

[163]  G. Di Iorio,et al.  Viral RNA in nerve tissues of patients with hepatitis C infection and peripheral neuropathy , 2003, Muscle & nerve.

[164]  X. Forns,et al.  HCV virological assessment. , 2006, Journal of hepatology.

[165]  Sheng-Nan Lu,et al.  Combination therapy with interferon‐α and ribavirin in patients with dual hepatitis B and hepatitis C virus infection , 2005, Journal of gastroenterology and hepatology.

[166]  D. Pillay,et al.  HIV and hepatitis C coinfection within the CAESAR study , 2004, HIV medicine.

[167]  B. Rehermann,et al.  Acute Hepatitis C: A Multifaceted Disease , 2005, Seminars in liver disease.

[168]  D. Amarapurkar Natural history of hepatitis C virus infection , 2000, Journal of gastroenterology and hepatology.

[169]  M. Ansar,et al.  Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran‐Rasht , 2002, Journal of viral hepatitis.

[170]  S. Vento,et al.  Infections and thalassaemia. , 2006, The Lancet. Infectious diseases.

[171]  N. Hayashi,et al.  Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. , 1994, Journal of hepatology.

[172]  R. Bennett,et al.  Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. , 1999, The American journal of gastroenterology.

[173]  A. Jenke,et al.  Peginterferon alfa‐2b plus ribavirin treatment in children and adolescents with chronic hepatitis C , 2005, Hepatology.

[174]  W. Kim,et al.  The burden of hepatitis C in the United States , 2002, Hepatology.

[175]  S. Malnick,et al.  Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. , 2006, Gastroenterology.

[176]  G. Fattovich,et al.  Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study , 1994 .

[177]  P. Sogni,et al.  Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus , 2004, British journal of haematology.

[178]  H. T. Head,et al.  Global surveillance and control of hepatitis C , 1999 .

[179]  J. Piette,et al.  Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. , 2002, Journal of hepatology.

[180]  R. Fisher,et al.  Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[181]  E. Sokal,et al.  Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[182]  T. Santantonio,et al.  Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. , 2005, Journal of hepatology.

[183]  R. Wiesner,et al.  Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. , 1998, Transplantation.

[184]  R. Purcell,et al.  Hepatitis C virus-associated fulminant hepatic failure. , 1996, The New England journal of medicine.

[185]  R. Wiesner,et al.  Management of ascites in patients with cirrhosis. What to do when diuretics fail. , 1992, Postgraduate medicine.

[186]  L. Seeff,et al.  The natural history of chronic hepatitis C infection. , 1996, European journal of gastroenterology & hepatology.

[187]  M. Weltman,et al.  Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. , 1995, Journal of viral hepatitis.

[188]  J. Goedert,et al.  Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[189]  R. Wiesner,et al.  Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome , 1998, Hepatology.

[190]  T. Berg,et al.  Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions , 1996, Hepatology.

[191]  R. Fanin,et al.  Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. , 1996, Blood.

[192]  B. Pereira,et al.  Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[193]  G. Colucci,et al.  Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. , 2003, Journal of hepatology.

[194]  J. Emond,et al.  Predictors of the cost of liver transplantation. , 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[195]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[196]  A. Floreani,et al.  Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis , 1999, Cancer.

[197]  Y. Shiratori,et al.  Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? , 2000, Journal of gastroenterology and hepatology.

[198]  S. Fucharoen,et al.  Prevalence and Clinical Significance of Hepatitis C Virus Infection in Thai Patients with Thalassemia , 2003, International journal of hematology.

[199]  F. Fabrizi,et al.  Treatment of chronic hepatitis C infection in patients with renal failure. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[200]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[201]  R. Chung,et al.  Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. , 1998, Transplantation.

[202]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[203]  A. Bruchfeld,et al.  Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[204]  D. S. Bowden,et al.  Chronic hepatitis C virus infection: genotyping and its clinical role. , 2006, Future microbiology.

[205]  J. Hoofnagle,et al.  National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002 , 2002, Hepatology.

[206]  D. Cortese,et al.  Hepatopulmonary Syndrome: Current Concepts in Diagnostic and Therapeutic Considerations , 1994 .

[207]  A. Mocroft,et al.  Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? , 2005, AIDS.

[208]  S. Martin [Hepatitis C in children]. , 2009, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[209]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.

[210]  J. Goedert,et al.  Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. , 2005, Blood.

[211]  W. Vogel,et al.  Prognosis and life expectancy in chronic liver disease , 1995, Digestive Diseases and Sciences.

[212]  M. Weltman,et al.  Coinfection with hepatitis B and C or B, C and δ viruses results in severe chronic liver disease and responds poorly to terferon‐a treatment , 1995 .

[213]  T. Liang,et al.  Hepatitis C — identifying patients with progressive liver injury , 2006, Hepatology.

[214]  S. Banks,et al.  The significance of antibody to hepatitis C virus in patients with chronic hepatitis B , 1991, Hepatology.

[215]  Ding‐Shinn Chen,et al.  Transmission of hepatitis C virus in Asia: past and present perspectives , 2000, Journal of gastroenterology and hepatology.

[216]  F. Farina,et al.  Longitudinal Long-term Follow-up Study of Children with Vertically Acquired Hepatitis C Virus Infection , 2006, The Journal of international medical research.

[217]  G. Dore,et al.  Long‐term outcome of vertically acquired and post‐transfusion hepatitis C infection in children , 2004, Journal of gastroenterology and hepatology.

[218]  G. Martorana,et al.  The long‐term course of chronic hepatitis B , 1999, Hepatology.

[219]  M. Shiffman,et al.  Use of diagnostic testing for managing hepatitis C virus infection. , 2004, Seminars in liver disease.

[220]  A. Alberti Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. , 2005, Journal of hepatology.

[221]  Z. Goodman,et al.  Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? , 2000, Hepatology.

[222]  K. Bjøro,et al.  Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study , 2004, Hepatology.

[223]  B Modell,et al.  Global Epidemiology of Hemoglobin Disorders , 1998, Annals of the New York Academy of Sciences.

[224]  G. Davis,et al.  Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. , 1994, Gastroenterology.

[225]  J. Córdoba,et al.  Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. , 1998, Journal of hepatology.

[226]  Claudio Michelassi,et al.  Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. , 2004, Seminars in arthritis and rheumatism.

[227]  A. Abdulla,et al.  Interferon-α in chronic hepatitis C infection in dialysis patients , 1999 .

[228]  I. Bilbao,et al.  Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. , 2005, Journal of hepatology.

[229]  A. Abdulla,et al.  Interferon-alpha in chronic hepatitis C infection in dialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[230]  F. Rosendaal,et al.  Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study 1 , 2006, Journal of thrombosis and haemostasis : JTH.

[231]  P. Cacoub,et al.  Fatigue in patients with chronic hepatitis C , 2002, Journal of viral hepatitis.

[232]  G. Zuin,et al.  Clinical features and progression of perinatally acquired hepatitis C virus infection , 2003, Journal of medical virology.

[233]  C. Alpers,et al.  Renal manifestations of hepatitis C virus infection. , 1994, Kidney international.

[234]  Y. Shiratori,et al.  Long‐term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C , 2000, Journal of gastroenterology and hepatology.

[235]  Shiuan-Chih Chen,et al.  Seroepidemiology of hepatitis A, B, C, and E viruses infection among preschool children in Taiwan , 2006, Journal of medical virology.

[236]  N. Gruener,et al.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. , 2003, Gastroenterology.

[237]  H. Margolis,et al.  The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States , 2000, Hepatology.

[238]  Seth D. Crockett,et al.  Annals of Clinical Microbiology and Anti microbials , 2005 .

[239]  Stephen L. Chen,et al.  The Natural History of Hepatitis C Virus (HCV) Infection , 2006, International journal of medical sciences.

[240]  D. Cooper,et al.  The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses , 2001, Current opinion in infectious diseases.

[241]  J. Lake,et al.  Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. , 1996, Transplantation.

[242]  J. Jeekel,et al.  RECOMBINANT LEUCOCYTE INTERFERON A INDUCES STEROID-RESISTANT ACUTE VASCULAR REJECTION EPISODES IN RENAL TRANSPLANT RECIPIENTS , 1984, The Lancet.

[243]  V. Paradis,et al.  An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection , 1995, Hepatology.

[244]  J. Ludwig,et al.  The long‐term pathological evolution of chronic hepatitis C , 1996, Hepatology.

[245]  A. Nicolucci,et al.  Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. , 2002, Blood.

[246]  M. Fried,et al.  Optimizing treatment regimens in hepatitis C. , 2006, Clinics in liver disease.

[247]  H. Van Vlierberghe,et al.  Treatment of acute hepatitis C with interferon α‐2b: early initiation of treatment is the most effective predictive factor of sustained viral response , 2004, Alimentary pharmacology & therapeutics.

[248]  A. Alberti,et al.  Management of hepatitis C. , 2003, Journal of hepatology.

[249]  N. Chalasani,et al.  Peginterferon alfa‐2a for hepatitis C after liver transplantation: Two randomized, controlled trials , 2005, Hepatology.

[250]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[251]  N. Terrault,et al.  Applicability, Tolerability and Efficacy of Preemptive Antiviral Therapy in Hepatitis C‐Infected Patients Undergoing Liver Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[252]  L. Ferrell,et al.  HCV-related fibrosis progression following liver transplantation: increase in recent years. , 2000, Journal of hepatology.

[253]  P. Giangrande,et al.  Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[254]  S. Sato,et al.  Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. , 1994, Journal of hepatology.

[255]  C. Chu,et al.  The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. , 1994, Gastroenterology.

[256]  S. Ryder Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults , 2003, Gut.

[257]  J. Berlin,et al.  The association between hepatitis C infection and survival after orthotopic liver transplantation. , 2002, Gastroenterology.

[258]  David H. Lee,et al.  Morbidity of Chronic Hepatitis C as Seen in a Tertiary Care Medical Center , 2004, Digestive Diseases and Sciences.

[259]  Ming‐Lung Yu,et al.  Viral Interaction and Responses in Chronic Hepatitis C and B Coinfected Patients with Interferon-Alpha plus Ribavirin Combination Therapy , 2005, Antiviral therapy.

[260]  Y. Liaw Concurrent hepatitis B and C virus infection: Is hepatitis C virus stronger? , 2001, Journal of gastroenterology and hepatology.

[261]  N. Afdhal,et al.  Duration of peginterferon therapy in acute hepatitis C: A randomized trial , 2006, Hepatology.

[262]  H. El‐Serag,et al.  Risk factors for the rising rates of primary liver cancer in the United States. , 2000, Archives of internal medicine.

[263]  G. Klintmalm,et al.  12‐month follow‐up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[264]  M. Vivarelli,et al.  Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[265]  D. Gretch,et al.  Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. , 1995, Journal of the American Society of Nephrology : JASN.

[266]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[267]  A. Andriulli,et al.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.

[268]  J. Piette,et al.  PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. , 2005, Arthritis and rheumatism.

[269]  P. Ruiz,et al.  Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. , 2005, Transplantation proceedings.

[270]  N. Afdhal The natural history of hepatitis C. , 2004, Seminars in liver disease.

[271]  O. Selberg,et al.  Identification of high‐ and low‐risk patients before liver transplantation: A prospective cohort study of nutritional and metabolic parameters in 150 patients , 1997, Hepatology.

[272]  F. Delmonico,et al.  Liver transplantation for primary hepatic cancer. , 1992, Transplantation.